The proposal to extend the IP waiver under the TRIPS Agreement for COVID-19 diagnostics and therapeutics would worsen the burden on innovators and have disastrous consequences for the American Southwest and the nation.
![](https://i0.wp.com/southwestpolicy.com/wp-content/uploads/2023/05/TRIPS-Waiver-SPPI-scaled-e1683561319913.jpg?fit=1200%2C600&ssl=1)
The proposal to extend the IP waiver under the TRIPS Agreement for COVID-19 diagnostics and therapeutics would worsen the burden on innovators and have disastrous consequences for the American Southwest and the nation.